CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
Public ClinicalTrials.gov record NCT02580448. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical study is to determine the safety, pharmacokinetics, pharmacodynamics and efficacy and activity of seviteronel, a lyase-selective inhibitor of CYP17, in patients with advanced breast cancer.
Study identification
- NCT ID
- NCT02580448
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 175 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2015 (Actual)
- Primary completion
- Jan 2019 (Actual)
- Completion
- Jan 2019 (Actual)
- Last update posted
- Feb 1, 2019
2015 – 2019
United States locations
- U.S. sites
- 36
- U.S. states
- 22
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Wallace Tumor Institute- University of Alabama | Birmingham | Alabama | 35249 | — |
| Clearview Cancer Institute | Huntsville | Alabama | 35805 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer Centers | Lakewood | Colorado | 80228 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| Florida Cancer Specialists- North | St. Petersburg | Florida | 33705 | — |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | — |
| SCRI - HCA Midwest Division | Kansas City | Kansas | 61432 | — |
| University of Louisville Hospital / James Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Maryland Oncology Hematology | Silver Spring | Maryland | 20902 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Masonic Cancer Center | Minneapolis | Minnesota | 55455 | — |
| Cancer Network/Oncology Associates PC | Omaha | Nebraska | 68118 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| North Shore Hematology Oncology Associates | East Setauket | New York | 11733 | — |
| Memorial Sloan Kettering | New York | New York | 10065 | — |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| Novant Health Presbyterian Medical Center - Oncology Research | Charlotte | North Carolina | 28204 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Oncology Hematology Care, Inc | Cincinnati | Ohio | 45242 | — |
| The Ohio State University | Columbus | Ohio | 43202 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
| Charleston Hematology and Oncology Associates | Charleston | South Carolina | 29414 | — |
| Precision Cancer Research/Brig Center for Cancer Care and Survivorship, LLC | Knoxville | Tennessee | 37909 | — |
| SCRI Tenessee Oncology Nashville | Nashville | Tennessee | 37203 | — |
| Mary Crowley Cancer Research Centers | Dallas | Texas | 75230 | — |
| The University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| The Center for Cancer and Blood Disorders (Fort Worth) | Fort Worth | Texas | 76104 | — |
| US Oncology | Fort Worth | Texas | 76177 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02580448, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2019 · Synced Nov 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02580448 live on ClinicalTrials.gov.